JP7834347B2 - 生体高分子標的特異的補体阻害剤及びその製造方法と応用 - Google Patents

生体高分子標的特異的補体阻害剤及びその製造方法と応用

Info

Publication number
JP7834347B2
JP7834347B2 JP2022568638A JP2022568638A JP7834347B2 JP 7834347 B2 JP7834347 B2 JP 7834347B2 JP 2022568638 A JP2022568638 A JP 2022568638A JP 2022568638 A JP2022568638 A JP 2022568638A JP 7834347 B2 JP7834347 B2 JP 7834347B2
Authority
JP
Japan
Prior art keywords
domain
crig
fusion protein
complement
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022568638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526218A5 (https=
JP2023526218A (ja
JPWO2021228052A5 (https=
Inventor
録英 李
Original Assignee
上海康景生物医薬科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海康景生物医薬科技有限公司 filed Critical 上海康景生物医薬科技有限公司
Publication of JP2023526218A publication Critical patent/JP2023526218A/ja
Publication of JP2023526218A5 publication Critical patent/JP2023526218A5/ja
Publication of JPWO2021228052A5 publication Critical patent/JPWO2021228052A5/ja
Priority to JP2025209848A priority Critical patent/JP2026035742A/ja
Application granted granted Critical
Publication of JP7834347B2 publication Critical patent/JP7834347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022568638A 2020-05-11 2021-05-10 生体高分子標的特異的補体阻害剤及びその製造方法と応用 Active JP7834347B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025209848A JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010393721.9 2020-05-11
CN202010393721.9A CN113637084B (zh) 2020-05-11 2020-05-11 生物大分子靶向特异性补体抑制剂及其制备方法与应用
PCT/CN2021/092861 WO2021228052A1 (zh) 2020-05-11 2021-05-10 生物大分子靶向特异性补体抑制剂及其制备方法与应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025209848A Division JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Publications (4)

Publication Number Publication Date
JP2023526218A JP2023526218A (ja) 2023-06-21
JP2023526218A5 JP2023526218A5 (https=) 2025-06-17
JPWO2021228052A5 JPWO2021228052A5 (https=) 2025-06-17
JP7834347B2 true JP7834347B2 (ja) 2026-03-24

Family

ID=78415417

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022568638A Active JP7834347B2 (ja) 2020-05-11 2021-05-10 生体高分子標的特異的補体阻害剤及びその製造方法と応用
JP2025209848A Pending JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025209848A Pending JP2026035742A (ja) 2020-05-11 2025-11-28 生体高分子標的特異的補体阻害剤及びその製造方法と応用

Country Status (6)

Country Link
US (1) US20230348554A1 (https=)
EP (1) EP4151659A4 (https=)
JP (2) JP7834347B2 (https=)
CN (2) CN113637084B (https=)
CA (1) CA3178088A1 (https=)
WO (1) WO2021228052A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114920849A (zh) * 2022-03-09 2022-08-19 安徽省立医院(中国科学技术大学附属第一医院) 一种靶向补体免疫抑制蛋白及其构建方法及应用
WO2025103318A1 (zh) * 2023-11-13 2025-05-22 沈阳三生制药有限责任公司 一种靶向C3b的双功能融合蛋白及其制备方法与用途
CN121159642B (zh) * 2025-11-20 2026-04-03 山东第二医科大学 补体c9迷你结合蛋白或其突变体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535062A (ja) 2013-09-05 2016-11-10 フーダン ユニバーシティ シャンハイ キャンサー センター 特異的補体系を標的化する阻害剤ならびにその調製方法および使用
WO2019075519A1 (en) 2017-10-18 2019-04-25 Csl Limited HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
WO2019218009A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
WO2020041644A1 (en) 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP3524620A1 (en) * 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
WO2017114401A1 (zh) * 2015-12-31 2017-07-06 江苏匡亚生物医药科技有限公司 具有补体调节活性的重组补体因子h-免疫球蛋白融合蛋白及其制备方法与应用
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535062A (ja) 2013-09-05 2016-11-10 フーダン ユニバーシティ シャンハイ キャンサー センター 特異的補体系を標的化する阻害剤ならびにその調製方法および使用
WO2019075519A1 (en) 2017-10-18 2019-04-25 Csl Limited HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF
WO2019218009A1 (en) 2018-05-16 2019-11-21 Csl Limited Soluble complement receptor type 1 variants and uses thereof
WO2020041644A1 (en) 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same

Also Published As

Publication number Publication date
CN115515985A (zh) 2022-12-23
CA3178088A1 (en) 2021-11-18
WO2021228052A1 (zh) 2021-11-18
JP2023526218A (ja) 2023-06-21
CN113637084A (zh) 2021-11-12
EP4151659A4 (en) 2024-07-24
EP4151659A1 (en) 2023-03-22
JP2026035742A (ja) 2026-03-04
US20230348554A1 (en) 2023-11-02
CN113637084B (zh) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7834347B2 (ja) 生体高分子標的特異的補体阻害剤及びその製造方法と応用
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
JP5902367B2 (ja) 抗体
ES2700149T3 (es) Proteínas de fusión de UTI
CN106279423B (zh) Slit2D2-HSA融合蛋白及其在抗肿瘤中的应用
JP2004203890A (ja) マクロファージ炎症蛋白変種
CN101175768B (zh) 促红细胞生成素变体
JP2018522547A (ja) Ｉｌ−３７バリアント
JP2021525283A (ja) ＣＤ３００ｃの発現抑制剤または活性抑制剤を含む癌の予防または治療用薬学的組成物
CN103601805B (zh) 一种人fgf21单克隆抗体的轻链和重链可变区
CN114686429A (zh) 一种激活nk细胞的肿瘤免疫治疗方法
CN102030822A (zh) 人类新细胞因子VSTM1-v2及其应用
JP5819439B2 (ja) 修飾されたヒト腫瘍壊死因子受容体−１ポリペプチドまたはその断片及びその製造方法
KR102315997B1 (ko) Baf57 재조합 융합 단백질 및 이의 용도
CN108295242A (zh) 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用
CN105693845B (zh) 一种cd40胞外区的表达纯化及其用途
EA038673B1 (ru) Плазмидная днк, кодирующая дефенсин hnp-1, либо hnp-2, либо hnp-3
CN1952129B (zh) Angptl4缺失突变体及其应用
HK40084879A (en) Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
HK40084870A (en) Biological macromolecular target-specific complement inhibitor, preparation method therefor, and application thereof
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
CN102732524A (zh) 类HRG的七鳃鳗Lj-RGD3全RGD缺失突变体Lj-112在抗肿瘤药物中的应用
WO2003057252A1 (en) Human mast cell-expressed membrane proteins
CN101017166A (zh) 人rtn4b蛋白在制备抗肿瘤药物中的应用
CN100443501C (zh) 人骨髓基质细胞来源的线粒体转运蛋白分子及其编码序列和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250318

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250609

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260304

R150 Certificate of patent or registration of utility model

Ref document number: 7834347

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150